Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/8339
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorKok, SHL-
dc.creatorChui, CH-
dc.creatorLam, WS-
dc.creatorChen, J-
dc.creatorLau, FY-
dc.creatorWong, RSM-
dc.creatorCheng, GYM-
dc.creatorTang, WK-
dc.creatorCheng, CH-
dc.creatorTang, JCO-
dc.creatorChan, ASC-
dc.date.accessioned2015-07-14T01:31:17Z-
dc.date.available2015-07-14T01:31:17Z-
dc.identifier.issn1107-3756-
dc.identifier.urihttp://hdl.handle.net/10397/8339-
dc.language.isoenen_US
dc.publisherSpandidos Publicationsen_US
dc.subjectCantharidinen_US
dc.subjectCaspaseen_US
dc.subjectLeukaemiaen_US
dc.titleMechanistic insight into a novel synthetic cantharidin analogue in a leukaemia modelen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage375-
dc.identifier.epage379-
dc.identifier.volume18-
dc.identifier.issue2-
dcterms.abstractCantharidin isolated from Mylabris caraganae and other insects is used traditionally as an anti-cancer drug especially on hepatoma and leukaemia. Previously, we demonstrated that the novel synthetic cantharidin analogue CAN 032 possessed apoptotic activity on two human hepatoma cell lines Hep3B hepatocellular carcinoma and SK-Hep-1 liver adenocarcinoma. However, its underlying mechanistic action on cancer cells remained unclear. Herein, we furthered our work by making use of KG1a acute myelogenous leukaemia (AML) and K562 chronic myelogenous leukaemia (CML) as experimental models. As anticipated, both leukaemia cell lines were sensitive to the cytotoxic action of CAN 032. The activity of CAN 032 was both dose- and time-course-dependent. CAN 032 readily inhibited the colony formation potential of both leukaemia cell lines. KG1a AML treated with CAN032 decreased G1 phase cell population, mitochondrial membrane potential collapse, caspase 3 activation and hence DNA fragmentation. Pre-incubation of leukaemia cells with the general caspase inhibitor Z-VAD-FMK could partially reversed the apoptotic action of CAN 032. This result suggested that the caspase-dependent pathway is necessary for the apoptotic action of CAN 032. CAN 032 provides a new direction for novel drug discovery in experimental cancer therapy.-
dcterms.bibliographicCitationInternational journal of molecular medicine, 2006, v. 18, no. 2, p. 375-379-
dcterms.isPartOfInternational journal of molecular medicine-
dcterms.issued2006-
dc.identifier.scopus2-s2.0-33847711240-
dc.identifier.eissn1791-244X-
dc.identifier.rosgroupidr28481-
dc.description.ros2005-2006 > Academic research: refereed > Publication in refereed journal-
Appears in Collections:Journal/Magazine Article
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

SCOPUSTM   
Citations

14
Last Week
0
Last month
Citations as of Aug 21, 2020

Page view(s)

135
Last Week
3
Last month
Citations as of Oct 18, 2020

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.